TheFly.com
Start Free Trial
<
Back to all Breaking News
FREQ
10/21/2021 07:10am
4
Street Research Stories
chevron_right
Frequency Therapeutics says 1st patient dosed in FX-322 Phase 2b SNHL study
Don't miss out!
We read the Wall Street research, SEC filings and press releases so you don't have to.
Sign up for our 14-day free trial to read this story.
Join Now
Learn More
Already have an account?
Sign In Here
Subscription Rates
dynamic_feed
Breaking News
search
Search
menu
Menu
